CONSTANT LEVERAGE SHORT - NOVO-NORDISK B | Real-time Euronext Paris 02:43:11 23/05/2024 pm IST | ||
| 1.39 EUR | -10.03% |
|
| Current month | -19.53% | ||
| 1 month | -29.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 1.39 | -10.03% |
| 22/24/22 | 1.545 | +3.69% |
| 21/24/21 | 1.49 | -15.34% |
| 17/24/17 | 1.76 | +6.67% |
| 16/24/16 | 1.65 | +2.48% |
Real-time Euronext Paris
Last update May 23, 2024 at 02:43 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| UB4MB | |
| ISIN | NLBNPNL2K183 |
| Date issued | 03/11/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.2 € |
|---|---|
| Lowest since issue | 1.38 € |
| Spread | 0.02 € |
| Spread % | 1.42% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- UB4MB Certificat
